Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gabriel Carvalho Pereira"'
Autor:
L. Karla Arruda, Mariana Paes Leme Ferriani, Janaina Michelle Lima Melo, Fernando Chahud, Julia S Costa, Orlando Trevisan-Neto, Adriana S. Moreno, Gabriel Carvalho Pereira, Pedro M M Garibaldi, Marina Célia Moraes Dias, Fabiola Traina
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
Background: Acquired angioedema due to C1 inhibitor deficiency (AAE-C1-INH) is a very rare disease. In clinical practice, it may be difficult to differentiate AAE-C1-INH from hereditary angioedema due to C1-INH deficiency (HAE-C1-INH). In both condit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7bae168ab0fd63b10dc54deea1ce529
Autor:
Camila Dermínio Donadel, Lucas Nonato de Oliveira, Rosane Maria Falasco Bolzoni, Marcelo Lourencini Puga, Ana Beatriz P.L. Stracieri, Maria Fernanda Lima Giuberti, Lucas Eduardo Botelho de Souza, Eduardo Magalhães Rego, Gil Cunha De Santis, Ana Carolina Jesus Vieira, Taisa Risque Fernandes, Fabiano Pieroni, Amanda Mizukami Martins, Dimas Tadeu Covas, Patricia Vianna Bonini Palma, Fernando Chahud, Leticia Maria Defendi Barboza, Patricia Oliveira da Cunha Terra, Maristela Delgado Orellana, Thalita Cristina de Mello Costa, Gabriel Carvalho Pereira, LC Palma, Caio Raony Farina Silveira, Renato L. Guerino-Cunha, Daianne Maciely Carvalho Fantacini, Sâmia Rigotto Caruso, Diego V. Clé, Benedito de Pina Almeida Prado, Juliana Bernardes Elias Dias, Rodrigo T. Calado, Anibal Basile
Publikováno v:
Blood. 138:4843-4843
Introduction: Treatment of diffuse large B cell lymphoma (DLBCL) may be a challenge for Latin American countries. Thus, novel strategies to reduce the economic burden of oncological care are necessary. In Brazil, the DLBCL annual incidence is approxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfd13a4155f1293da30f405bf6abbf73
https://doi.org/10.1182/blood-2021-154217
https://doi.org/10.1182/blood-2021-154217
Autor:
Luisa Espirito Santo Oliveira, Fabiola Traina, Lorena Lobo de Figueiredo-Pontes, Fernanda Silva, Gabriel Carvalho Pereira, Belinda Pinto Simões, LC Palma, Pedro M M Garibaldi
Publikováno v:
Blood. 134:5916-5916
Background: The treatment of chronic myeloid leukemia (CML) was revolutionized by the approval of Gleevec (imatinib mesylate) by the FDA in 2001. In low-middle-income countries, due to economic issues related to the high cost of this treatment, scien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::129486a8cc74fbd4682409268de44f89
https://doi.org/10.1182/blood-2019-132045
https://doi.org/10.1182/blood-2019-132045